ArticleTranslational cancer research2025
Albiflorin enhances the antitumor effects of propofol in hepatocellular carcinoma cells by inhibiting the Wnt/β-catenin signaling activation.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated experimental and network pharmacology analyses reveal inhibitory effects of albiflorin on renal cell carcinoma cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most common types of primary liver cancer worldwide. It is characterized by high heterogeneity and poor prognosis, and current treatment outcomes remain limited. Studies have shown that propofol possesses certain anticancer properties. However, the combined effects of albiflorin and the underlying mechanisms remain unclear. This study aimed to evaluate the anticancer activity of albiflorin in HCC, further investigate the combined effects and underlying mechanism of albiflorin and propofol. Methods: Huh-7 cells were treated with different concentrations of albiflorin (0, 25, 50, and 100 μg/mL) and propofol (0, 30, 60, and 120 μM), either alone or in combination. The effects on cell proliferation, apoptosis, migration, and invasion were evaluated. Cell proliferation was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Apoptosis and epithelial-mesenchymal transition (EMT) were measured by flow cytometry and western blotting, and cell migration and invasion were evaluated using Transwell assays. Additionally, the expression of key Wnt/β-catenin signaling molecules was analyzed by western blotting and reverse transcription-quantitative polymerase chain reaction to explore potential mechanisms. Results: Both albiflorin and propofol alone inhibited the proliferation, migration, invasion, and EMT of Huh-7 cells in a dose-dependent manner and promoted apoptosis. The combination of albiflorin and propofol effectively enhanced the inhibitory effects of propofol on HCC cells. Mechanistic studies revealed that the combined treatment significantly downregulated the expression of Wnt3a and β-catenin, suggesting that the antitumor effects may be mediated through the suppression of the Wnt/β-catenin signaling pathway. Conclusions: Albiflorin and propofol exert synergistic inhibitory effects on HCC cell proliferation, migration, invasion, and EMT while promoting apoptosis. These effects are likely associated with suppression of Wnt/β-catenin signaling. This study provides new experimental evidence supporting the development of multitargeted combination therapies and identifies potential molecular targets for comprehensive HCC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.